GLOW

GLOW 70 mg is a three-component research blend containing GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg. SARMs Revolution Lab offers it for laboratory research in Canada. Evidence about each separate material does not establish synergy, compatibility or clinical efficacy for the combined vial.

GLOW 70 mg research blend information

Researchers should confirm component identity, ratios and batch-specific analytical documentation before designing an experiment.

What is the GLOW peptide blend?

GLOW combines a copper-binding tripeptide, an experimental pentadecapeptide and a material associated with thymosin beta-4-fragment research. Each component has a different evidence base and may be measured through different analytical methods.

GHK-Cu literature includes matrix-remodelling and cell-response models. BPC-157 research is mostly preclinical. TB-500 terminology is commercially inconsistent and should not automatically be treated as full-length recombinant thymosin beta-4.

Has the complete GLOW blend been studied?

No controlled human study for this exact 50 mg/10 mg/10 mg formulation was identified. Claims that the three ingredients reproduce consecutive “phases of healing” oversimplify complex biology and are not established by a trial of the finished blend.

Combination research also raises questions about stability, analytical separation, concentration and interaction. Those questions should be tested rather than assumed.

GLOW evidence and regulatory limits

This product should not be represented as proven to repair tendons, heal injuries, regenerate tissue or accelerate recovery. This page does not provide dosage, reconstitution, injection, combination or treatment advice.

GLOW 70 mg frequently asked questions

What is in GLOW?

The listing identifies GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg.

What is the total listed content?

The three listed components total 70 mg.

Does evidence for one ingredient prove the blend?

No. Evidence is compound-, formulation- and model-specific.

Is TB-500 identical to full-length thymosin beta-4?

No identity should be assumed from the commercial name. Sequence and batch documentation matter.

Does this page include a protocol?

No. It does not provide mixing, dosage, injection or self-administration instructions.

Where can researchers read about the components?

See the individual pages for GHK-Cu, BPC-157 and TB-500.

Scientific references

• The human tripeptide GHK and tissue remodelling. 2008.
• Systematic review of BPC-157 research. 2025.
• Review of thymosin beta-4 structure and biological properties. 2010.

Research-use notice: GLOW 70 mg is offered strictly for laboratory research and analytical work. It is not intended for human consumption, self-administration, diagnosis, treatment or veterinary use.